https://www.globenewswire.com/news-release/2020/12/16/2145831/0/en/Novartis-announces-positive-FDA-Advisory-Committee-recommendation-for-use-of-Entresto-to-treat-patients-with-HFpEF.html
So Novartis just announced they received a 12-1 vote on their product Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF). The drug was shown to reduce hospitalization.
MESO's rex-L shows no reduction in hospitilization, but 60% improved mortality. I understand Novartis product Entresto shows significant reduction in hospitalization and 20% reduction in mortality.
Given the rush for a pause, then trading halt may coincide with the ODAC vote for Novartis, could it be that a JV between the two is announced.
CHF patients could receive both Entresto and Rex-L and together reduce mortality and hospitalization all in one?
Ann: Trading halt, page-368
-
- There are more pages in this discussion • 429 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.000(0.00%) |
Mkt cap ! $1.370B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.18 | $2.446M | 2.047M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 10544 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 27409 | 10 |
View Market Depth
| Last trade - 11.31am 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |